Agios Pharmaceuticals (AGIO) News Today

Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 52-Week High at $50.35

BNP Paribas Financial Markets decreased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 74.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,575 shares of the

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 5.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,108,613 shares of the biopharmaceutical compa

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totalling 3,130,000 shares, a decline of 25.8% from the June 15th total of 4,220,000 shares. Based on an average daily volume of 802,000 shares, the short-interest ratio is currently 3.9 days. Currently, 5.7% of the shares of the stock are short sold.

GSA Capital Partners LLP reduced its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 70.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,853 shares of the biopharmaceutical company's stock

Nordea Investment Management AB grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 13.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 266,588 shares of the biophar

Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.6%

Oak Ridge Investments LLC bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 40,043 shares of the biopharmaceutical company's stock, valued at ap

StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 4,220,000 shares, a drop of 5.6% from the May 31st total of 4,470,000 shares. Based on an average daily trading volume, of 795,400 shares, the days-to-cover ratio is presently 5.3 days. Approximately 7.6% of the company's shares are short sold.

Agios Pharmaceuticals (NASDAQ:AGIO) Trading 4% Higher

Fisher Asset Management LLC lessened its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 711,521 shares of the biopharmaceutical company's stock after s

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down to $46.77

JPMorgan Chase & Co. restated a "neutral" rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a report on Thursday.

Frazier Life Sciences Management L.P. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 79.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 523,166 shares of the biopharmaceutic

First Trust Advisors LP grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,818,643 shares of the bioph

Rafferty Asset Management LLC grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 14.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 153,485 shares of the biopharmaceutical company's stock after acquiring

Allianz Asset Management GmbH boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 38.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,111 shares of the biopharmaceutical company's stock after acquiring an addi

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2027 earnings estimates for Agios Pharmaceuticals in a report issued on Monday, June 3rd. Leerink Partnrs analyst A. Berens anticipates that the biopharmaceutical company will po

Campbell & CO Investment Adviser LLC purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,686 shares of the biopharm

Armistice Capital LLC boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,524,000 shares of

The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a "neutral" rating in a research note on Tuesday.

Agios Pharmaceuticals (NASDAQ:AGIO) Trading Up 3.1% on Analyst Upgrade

Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month High at $41.74

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) saw unusually large options trading activity on Monday. Stock investors bought 3,284 put options on the company. This is an increase of 1,077% compared to the average volume of 279 put options.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a note issued to investors on Tuesday, May 28th. Leerink Partnrs analyst A. Berens now anticipates that

Trexquant Investment LP bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 54,541 shares of the biopharmaceutical compan

StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.

Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month High at $39.70

Dimensional Fund Advisors LP boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 5.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,596,764 shares of the biopharmaceutical company's stock after purchasing

BNP Paribas Financial Markets grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 111.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 125,309 shares of the biopharmaceutical company's stock aft

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Zacks Research upped their Q2 2024 earnings estimates for Agios Pharmaceuticals in a research note issued on Monday, May 20th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post